Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 75
Filter
Add more filters










Publication year range
1.
Article in Russian | MEDLINE | ID: mdl-20734716

ABSTRACT

AIM: To study the effect of chimeric E7 protein of human papillomavirus type 18 on activation of adaptive immunity in absence of adjuvant. MATERIALS AND METHODS: Chimeric protein was genetically engineered and represents the protein molecule consisting of full-size E7 oncoprotein and heat-shock protein 70 (HSP70) of Mycobacterium tuberculosis in one polypeptide chain. Antibody titers as well as isotypes and subisotypes of immunoglobulins were measured by ELISA in sera of immunized animals. RESULTS: It was shown that studied construction E7 (HPV-18)-HSP70 significantly increases titers of antibodies to E7 protein of HPV type 18 and have cross-reactive antigenic activity with E7 protein of HPV type 16. Immunization with chimeric protein resulted in increase of IgG1 and IgG2b levels and decrease of IgG2a and IgM levels. CONCLUSION: . Oncoprotein E7 included in chimeric construction with HSP70 could be used for further studies on development of therapeutic vaccine for treatment of cervical cancer and precancerous lesions. Skew of immune response to Th2 type after intraperitoneal administration of the studied construction points to necessity for control of immunity during such studies.


Subject(s)
Bacterial Proteins/immunology , DNA-Binding Proteins/immunology , HSP70 Heat-Shock Proteins/immunology , Oncogene Proteins, Viral/immunology , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/immunology , Recombinant Fusion Proteins/immunology , Uterine Cervical Neoplasms/prevention & control , Adjuvants, Immunologic/administration & dosage , Animals , Antibodies, Viral/blood , Antibody Specificity , Bacterial Proteins/administration & dosage , Bacterial Proteins/genetics , DNA-Binding Proteins/administration & dosage , DNA-Binding Proteins/genetics , Drug Evaluation, Preclinical , Female , HSP70 Heat-Shock Proteins/administration & dosage , HSP70 Heat-Shock Proteins/genetics , Humans , Immunization , Immunization Schedule , Immunoglobulin A/blood , Immunoglobulin G/blood , Immunoglobulin M/blood , Injections, Intraperitoneal , Male , Mice , Oncogene Proteins, Viral/administration & dosage , Oncogene Proteins, Viral/genetics , Papillomavirus Infections/blood , Papillomavirus Vaccines/administration & dosage , Papillomavirus Vaccines/genetics , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/genetics , Uterine Cervical Neoplasms/immunology , Uterine Cervical Neoplasms/virology
2.
Izv Akad Nauk Ser Biol ; (3): 375-9, 2010.
Article in Russian | MEDLINE | ID: mdl-20583622

ABSTRACT

Repeated (over 7 days) intranasal introduction of the Pro-Gly-Pro-Leu peptide into animals at a dose of 1 mg/kg before injection of the diabetogenic metabolite alloxan provided effective protection of an organism against development of insulin-dependent diabetes mellitus and prevented development of hypercoagulating alterations in the system of hemostasis. An increasing in the anticoagulating and fibrinolytic activities in rat blood plasma was detected. The peptide under study also showed antidiabetogenic action: repeated intranasal introduction of the Pro-Gly-Pro-Leu peptide into animals for 7 days inhibited development of diabetes symptoms in rats pretreated with alloxan.


Subject(s)
Diabetes Mellitus, Experimental/prevention & control , Diabetes Mellitus, Type 1/prevention & control , Fibrinolytic Agents/therapeutic use , Hypoglycemic Agents/therapeutic use , Oligopeptides/therapeutic use , Administration, Intranasal , Alloxan , Animals , Blood Glucose/analysis , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/chemically induced , Fibrinolysis/drug effects , Fibrinolytic Agents/administration & dosage , Hypoglycemic Agents/administration & dosage , Male , Oligopeptides/administration & dosage , Rats , Time Factors
3.
Izv Akad Nauk Ser Biol ; (1): 109-14, 2010.
Article in Russian | MEDLINE | ID: mdl-20235435

ABSTRACT

Daily intramuscular injections of the arginine-heparin complex for 5 days before injection of diabetogenic metabolite alloxan did not cause insulin-dependent diabetes in animals for 3 weeks. As a result of these injections, the anticoagulant fibrinolytic pattern of the anticoagulant system was activated and the platelet aggregation decreased. This effect held for 7 days after injection.


Subject(s)
Anticoagulants/pharmacology , Arginine/pharmacology , Diabetes Mellitus, Experimental/prevention & control , Fibrinolysis/drug effects , Heparin/pharmacology , Platelet Activation/drug effects , Animals , Male , Rats , Time Factors
4.
Izv Akad Nauk Ser Biol ; (6): 740-4, 2009.
Article in Russian | MEDLINE | ID: mdl-20143634

ABSTRACT

It was shown that chronic (over 7 days) intranasal injection of the Pro-Gly-Arg tripeptide to rats in the dose 1 mg/kg before the injection of a diabetogenic dose of alloxan, promotes effective defense against development of insulin dependent diabetes mellitus. At the same time, the tetra-peptide Pro-Gly-Pro-Arg did not show a hypoglycemic affect during diabetes mellitus provocation. Administration of Pro-Gly-Arg and Pro-Gly-Pro-Arg peptides also activates anticoagulation potential.


Subject(s)
Diabetes Mellitus, Experimental/prevention & control , Hypoglycemic Agents/pharmacology , Oligopeptides/pharmacology , Administration, Intranasal , Animals , Blood Coagulation/drug effects , Male , Rats , Time Factors
5.
Izv Akad Nauk Ser Biol ; (5): 602-5, 2006.
Article in Russian | MEDLINE | ID: mdl-17086970

ABSTRACT

A significant and considerable decrease in abnormally high platelet aggregation has been demonstrated after intramuscular administration of sodium adenosine triphosphate (ATP) to rats with depressed anti-coagulant system (in aging rats at the age of 11-12 months) and to rats with experimental diabetes both preliminarily and at the background of progressing diabetes. The elimination of one of thrombotic risk factors (decreasing elevated platelet aggregation) points to possible antithrombotic activity of ATP under these experimental conditions.


Subject(s)
Adenosine Triphosphate/therapeutic use , Aging/blood , Diabetes Mellitus, Experimental/blood , Platelet Aggregation Inhibitors/therapeutic use , Platelet Aggregation/drug effects , Adenosine Triphosphate/administration & dosage , Adenosine Triphosphate/pharmacology , Animals , Dose-Response Relationship, Drug , Injections, Intramuscular , Injections, Intravenous , Male , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/pharmacology , Rats
6.
Izv Akad Nauk Ser Biol ; (3): 381-4, 2006.
Article in Russian | MEDLINE | ID: mdl-16771153

ABSTRACT

Repeated intramuscular administration of low molecular weight heparin-collagen complex proved to increase fibrinolytic activity and to decrease platelet aggregation in the blood of rats (11 months) with depressed anticoagulant system. Administration of diabetogenic alloxan dose induced no diabetes mellitus in such animals.


Subject(s)
Collagen/administration & dosage , Diabetes Mellitus, Experimental , Fibrinolysis/drug effects , Heparin, Low-Molecular-Weight/administration & dosage , Platelet Aggregation/drug effects , Alloxan/administration & dosage , Alloxan/antagonists & inhibitors , Alloxan/toxicity , Animals , Collagen/antagonists & inhibitors , Diabetes Mellitus, Experimental/chemically induced , Heparin, Low-Molecular-Weight/antagonists & inhibitors , Injections, Intramuscular , Rats
7.
Izv Akad Nauk Ser Biol ; (1): 77-80, 2006.
Article in Russian | MEDLINE | ID: mdl-16521542

ABSTRACT

Repeated intramuscular administration of the heparin-adenosine triphosphate (ATP) complex or ATP increased plasma anticoagulant and fibrinolytic activities and depressed the anticoagulation system in rats at the age of 10-11 months. Diabetogenic dose of alloxan induced no diabetes mellitus in such animals.


Subject(s)
Adenosine Triphosphate/administration & dosage , Anticoagulants/administration & dosage , Diabetes Mellitus, Experimental/prevention & control , Heparin/administration & dosage , Hypoglycemic Agents/administration & dosage , Alloxan/administration & dosage , Animals , Fibrinolysis/drug effects , Male , Molecular Weight , Rats , Rats, Mutant Strains
8.
Izv Akad Nauk Ser Biol ; (5): 581-4, 2004.
Article in Russian | MEDLINE | ID: mdl-15559137

ABSTRACT

We studied the effect of chronic intraperitoneal administration of heparin-lysine complex on the state of the hemostatic and insular systems in young and senescent animals (rats). This complex exerted a positive effect on physiological function of the coagulant, anticoagulant, and fibrinolytic components of the hemostatic system in the norm and in developing experimental alloxan diabetes. In this case, both the complex and its components, lysine and heparin, had a pronounced antidiabetogenic effect.


Subject(s)
Anticoagulants/administration & dosage , Diabetes Mellitus, Experimental/physiopathology , Hemostasis/drug effects , Heparin/administration & dosage , Lysine/administration & dosage , Animals , Diabetes Mellitus, Experimental/drug therapy , Hemostasis/physiology , Male , Rats
9.
Izv Akad Nauk Ser Biol ; (3): 340-4, 2004.
Article in Russian | MEDLINE | ID: mdl-15354961

ABSTRACT

Natural heparin complexes proved to activate the anticoagulation system. The obtained experimental data convincingly confirm that glutamic acid alone, and particularly in a complex with heparin, has a considerable preventive potential and efficiently protects experimental animals with induced diabetes mellitus.


Subject(s)
Anticoagulants/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Glutamic Acid/pharmacology , Heparin/pharmacology , Hypoglycemic Agents/pharmacology , Alloxan , Animals , Anticoagulants/therapeutic use , Blood Glucose/drug effects , Blood Platelets , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/metabolism , Glutamic Acid/chemistry , Heparin/chemistry , Hypoglycemic Agents/therapeutic use , Insulin/blood , Male , Rats
10.
Vopr Med Khim ; 46(2): 149-54, 2000.
Article in Russian | MEDLINE | ID: mdl-10885035

ABSTRACT

The chronic heparin deficiency achieved by long-term treatment (for 3 weeks) with protamine-sulfate is accompanied by the development of stable hyperglycemia, decreased glucose tolerance, and the appearance of insulin resistance. Administration of exogenous heparin promotes the restoration of normoglycemia.


Subject(s)
Heparin/deficiency , Hyperglycemia/etiology , Insulin Resistance , Animals , Glucose Tolerance Test , Heparin/administration & dosage , Heparin/therapeutic use , Heparin Antagonists/administration & dosage , Hyperglycemia/drug therapy , Male , Protamines/administration & dosage , Rats
11.
Vopr Med Khim ; 44(3): 256-61, 1998.
Article in Russian | MEDLINE | ID: mdl-9703625

ABSTRACT

Administration of peony roots preparations provides the stable prophylactic effect against the development of experimental alloxan diabetes. This preparation and its complex with aspirin conserves the normal hemostatic system status and moderates the insular system disturbances. These preparations provide greater survival of animals.


Subject(s)
Diabetes Mellitus, Experimental/prevention & control , Hemostasis/drug effects , Insulin/metabolism , Plant Extracts/pharmacology , Plant Roots/chemistry , Animals , Aspirin/pharmacology , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/physiopathology , Male , Rats
13.
Patol Fiziol Eksp Ter ; (1): 21-3, 1996.
Article in Russian | MEDLINE | ID: mdl-8657446

ABSTRACT

Oral heparin given to rats was found to neutralize the hyperglycemic and hypoinsulinemic effects of diabetogenic factor and to produce a protective action by preventing the animals from the diabetogenic action of alloxan. The chronic oral heparin use alleviated the course of severe alloxan diabetes in rats, by contributing to the reduction of hyperglycemic levels, to the elevation of blood insulin concentrations, thus promoting their higher survival.


Subject(s)
Diabetes Mellitus, Experimental/prevention & control , Heparin/pharmacology , Hyperglycemia/prevention & control , Administration, Oral , Animals , Hyperglycemia/etiology , Male , Rats
15.
Vopr Med Khim ; 39(1): 20-2, 1993.
Article in Russian | MEDLINE | ID: mdl-8498064

ABSTRACT

Vitamin A deficiency contributed to higher incidence of abnormalities in experimental animals with insulin-dependent diabetes induced by alloxan. However, the similar doses of alloxan did not cause diabetes in the animals maintained on a diet containing adequate amounts of vitamin A used for prophylactic purposes for a long time. The natural diabetogenic factor specific to insulin-dependent diabetes was not found in the blood serum of these animals.


Subject(s)
Diabetes Mellitus, Experimental/prevention & control , Vitamin A/therapeutic use , Alloxan , Animals , Blood Glucose/analysis , Male , Rats
16.
Vopr Med Khim ; 37(4): 40-3, 1991.
Article in Russian | MEDLINE | ID: mdl-1750208

ABSTRACT

Implantation of beta-cells allogenic culture into animals with alloxan diabetes did not produce persistent positive effect. The implanted beta-cells lost their viability as a result of toxic effect of natural diabetogenic factor occurring in blood plasma during insulin-dependent diabetes. Long-term administration of heparin into these animals within first 90 days of the experiment enabled to avoid the negative phenomenon and to neutralize the diabetogenic factor activity. Under these conditions the implanted beta-cells effectively produced endogenous insulin and the symptoms of diabetes disappeared within 14 months.


Subject(s)
Diabetes Mellitus, Experimental/metabolism , Insulin/biosynthesis , Alloxan/pharmacology , Animals , Blood Glucose/analysis , Islets of Langerhans Transplantation , Male , Pituitary Hormones/blood , Rats
17.
Patol Fiziol Eksp Ter ; (2): 46-7, 1991.
Article in Russian | MEDLINE | ID: mdl-1881712

ABSTRACT

The results of experimental studies bear evidence that the pancreas of healthy animals produces a humoral factor which differs from insulin and prevents the development of alloxan diabetes. The pancreas of diabetic animals loses the above-mentioned activity and produces into the blood plasma a natural diabetogenic factor which promotes the development of alloxan diabetes.


Subject(s)
Diabetes Mellitus, Experimental/physiopathology , Pancreas/metabolism , Pituitary Hormones/physiology , Animals , Pituitary Hormones/biosynthesis
19.
Probl Endokrinol (Mosk) ; 36(1): 25-8, 1990.
Article in Russian | MEDLINE | ID: mdl-2330356

ABSTRACT

The authors analyzed the results of investigation of insulin residual secretion determined by the concentration of C-peptide in response to the stimulation of 1 mg of glucagon. The blood level of the diabetogenic factor (DGF) and activity of the anticoagulative system (ACS) were studied in parallel in patients with insulin-dependent type of diabetes mellitus before and after heparin therapy. The blood DGF disappeared, ACS function was restored, and the patient's body resistance to blood hypercoagulation developed against a background of heparin therapy. A decrease in insulin residual secretion was shown to be related to a duration of diabetes mellitus.


Subject(s)
Blood Coagulation/physiology , C-Peptide/blood , Diabetes Mellitus, Type 1/blood , Heparin/therapeutic use , Pituitary Hormones/blood , Adolescent , Adult , Blood Coagulation/drug effects , C-Peptide/drug effects , Child , Chronic Disease , Diabetes Mellitus, Type 1/drug therapy , Female , Glucagon , Humans , Male , Time Factors
20.
Probl Endokrinol (Mosk) ; 35(6): 78-81, 1989.
Article in Russian | MEDLINE | ID: mdl-2622891

ABSTRACT

An effective model of stable and prolonged alloxan diabetes in rats was described. For this purpose the rats were kept on a synthetic diet with the increased level of proteins and lipids during 1-2 mos. before i.v. injection of alloxan at a dose of 35-40 mg/kg with subsequent feeding by this ration during all the time of the experiment. This model of experimental diabetes ensures a high level of hyperglycemia and hypoinsulinemia as well as a high titer of activity of the diabetogenic factor, to the same extent, as in rats kept on the common laboratory ration.


Subject(s)
Diabetes Mellitus, Experimental/etiology , Dietary Fats/administration & dosage , Dietary Proteins/administration & dosage , Alloxan/toxicity , Animals , Blood Glucose/analysis , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/mortality , Disease Models, Animal , Insulin Antibodies/analysis , Male , Pituitary Hormones/blood , Rats , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...